|
1
|
Shimosato Y, Kameya T, Ngai K and Suemasu
K: Squamous cell carcinoma of the thymus. An analysis of eight
cases. Am J Surg Pathol. 1:109–121. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Weksler B, Dhupar R, Parikh V, Nason KS,
Pennathur A and Ferson PF: Thymic carcinoma: A multivariate
analysis of factors predictive of survival in 290 patients. Ann
Thorac Surg. 95:299–303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao Y, Zhao H, Hu D, Fan L, Shi J and
Fang W: Surgical treatment and prognosis of thymic squamous cell
carcinoma: A retrospective analysis of 105 cases. Ann Thorac Surg.
96:1019–1024. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suster S and Rosai J: Thymic carcinoma. A
clinicopathologic study of 60 cases. Cancer. 67:1025–1032. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hsu CP, Chen CY, Chen CL, Lin CT, Hsu NY,
Wang JH and Wang PY: Thymic carcinoma. Ten year' experience in
twenty patients. J Thorac Cardiovasc Surg. 107:615–620.
1994.PubMed/NCBI
|
|
6
|
Takeda S, Sawabata N, Inoue M, Koma M,
Maeda H and Hirano H: Thymic carcinoma. Clinical institutional
experience with 15 patients. Eur J Cardiothorac Surg. 26:401–406.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Agatsuma T, Koizumi T, Kanda S, Ito M,
Urushihata K, Yamamoto H, Hanaoka M and Kubo K: Combination
chemotherapy with doxorubicin, vincristine, cyclophosphamide, and
platinum compounds for advanced thymic carcinoma. J Thorac Oncol.
6:2130–2134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H,
Kubota K, Kakinuma R, Nagai K, Suga M and Nishiwaki Y: Weekly
chemotherapy with cisplatin, vincristine, doxorubicin, and
etoposide is an effective treatment for advanced thymic carcinoma.
Cancer. 98:926–931. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okuma Y, Hosomi Y, Takagi Y, Iguchi M,
Okamura T and Shibuya M: Cisplatin and irinotecan combination
chemotherapy for advanced thymic carcinoma: Evaluation of efficacy
and toxicity. Lung Cancer. 74:492–496. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Magois E, Guigay J, Blancard PS, Margery
J, Milleron B, Lher P and Jounieaux V: Multimodal treatment of
thymic carcinoma: Report of nine cases. Lung Cancer. 59:126–132.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oguri T, Achiwa H, Kato D, Maeda H, Niimi
T, Sato S and Ueda R: Efficacy of docetaxel as a second-line
chemotherapy for thymic carcinoma. Chemotherapy. 50:279–282. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang Y, Padda SK, Piess JW, West RB, Neal
JW and Wakelee HA: Pemetrexed in patients with thymic malignancies
previously treated with chemotherapy. Lung Cancer. 87:34–38. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Okuma Y, Shimokawa T, Takagi Y, Hosomi Y,
Iguchi M, Okamura T and Shibuya M: S-1 is an acrive anticancer
agent for advanced thymic carcinoma. Lung Cancer. 70:357–363. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tagawa T, Ohta M, Kuwata T, Awaya H and
Ishida T: S-1 plus cisplatin chemotherapy with concurrent radiation
for thymic basaloid carcinoma. J Thorac Oncol. 5:572–573. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Altaha R, Liang X, Yu JJ and Reed E:
Excision repair cross complementing-group 1: Gene expression and
platinum resistance. Int J Mol Med. 14:959–970. 2004.PubMed/NCBI
|
|
16
|
Lord RV, Brabender J, Gandara D, Alberola
V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón
M, et al: Low ERCC1 expression correlates with prolonged survival
after cisplatin plus gemcitabine chemotherapy in non-small cell
lung cancer. Clin Cancer Res. 8:2286–2291. 2002.PubMed/NCBI
|
|
17
|
Metzger R, Leichman CG, Danenberg KD,
Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H,
Laine L, et al: ERCC1 mRNA levels complement thymidylate synthase
mRNA levels in predicting response and survival for gastric cancer
patients receiving combination cisplatin and fluorouracil
chemotherapy. J Clin Oncol. 16:309–316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katsetos CD, Legido A, Perentes E and Mörk
SJ: Class III beta-bululin isotype: A key cytoskeletal protein at
the crossroads of developmental neurobiology and tumor
neuropathology. J Child Neurol. 18:851–866; discussion 867. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lu Q and Luduena RF: Removal of beta III
isotype enhances taxol induced microtubule assembly. Cell Struct
Funct. 18:173–182. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kamath K, Wilson L, Cabral F and Jordan
MA: BetaIII-tubulin induces paclitaxel resistance in association
with reduced effects on microtubule dynamic instability. J Biol
Chem. 280:12902–12907. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okuda K, Sasaki H, Dumontet C, Kawano O,
Yukiue H, Yokoyama T, Yano M and Fujii Y: Expression of excision
repair cross-complementation group 1 and class III beta-tubulin
predict survival after chemotherapy for completely resected
non-small cell lung cancer. Lung Cancer. 62:105–112. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Masaoka A, Monden Y, Nakahara K and
Tanioka T: Follow-up study of thymomas with special reference to
their chlinical stages. Cancer. 48:2485–2492. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern
Cooperative Oncology Group: Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lilenbaum RC, Herndon JE II, List MA,
Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W,
Chahinian P, et al: Single-agent versus combination chemotherapy in
advanced non-small-cell lung cancer: The cancer and leukemia group
B (study 9730). J Clin Oncol. 23:190–196. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lemma GL, Lee JW, Aisner SC, Langer CJ,
Tester WJ, Johnson DH and Loehrer PJ Sr: Phase II study of
carboplatin and paclitaxel in advanced thymoma and thymic
carcinoma. J Clin Oncol. 29:2060–2065. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Igawa S, Murakami H, Takahashi T, Nakamura
Y, Tsuya A, Naito T, Kaira K, Ono A, Shukuya T, Tamiya A, et al:
Efficacy of chemotheraoy with carboplatin and paclitaxel for
unresectable thymic carcinoma. Lung Cancer. 67:194–197. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Furugen M, Sekine I, Tsuta K, Horinouchi
H, Nokihara H, Yamamoto N, Kubota K and Tamura T: Combination
chemotherapy with carboplatin and paclitaxel for advanced thymic
cancer. Jpn J Clin Oncol. 41:1013–1016. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hirai F, Yamanaka T, Taguchi K, Daga H,
Ono A, Tanaka K, Kogure Y, Shimizu J, Kimura T, Fukuoka J, et al: A
multicenter phase II study of carboplatin and paclitaxel for
advanced thymic carcinoma: WJOG4207L. Ann Oncol. 26:363–368. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weiss GJ: Thymic carcinoma: Current and
future therapeutic interventions. Expert Opin Investig Drugs.
19:1007–1016. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kaira K, Serizawa M, Koh Y, Miura S, Kaira
R, Abe M, Nakagawa K, Ohde Y, Okumura T, Naito T, Murakami H,
Takahashi T, Kondo H, Nakajima T, Endo M and Yamamoto N: Expression
of excision repair cross-complementation group 1, breast cancer
susceptibility 1, and β III-tubulin in thymic epithelial tumors. J
Thorac Oncol. 6:606–613. 2011. View Article : Google Scholar : PubMed/NCBI
|
